Independent firm supports Conformis’ pending merger

ISS, an independent proxy advisory firm, recommended stockholders vote in favor of Conformis’ pending merger with Restor3d.

Advertisement

Restor3d is expected to acquire Conformis for $2.27 per share, according to an Aug. 21 news release. The deal was first announced in June.

Under the pending deal, Restor3d will acquire all of the outstanding stock shares of Conformis in cash. Conformis’ board of directors unanimously approved the transaction.

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Orthopedic

  • CMS has published the list of hospitals that will take part in its Comprehensive Care for Joint Replacement Expanded Model,…

  • Stryker CEO Kevin Lobo will transition to executive chair of the board of directors Jan. 1, 2027, as President and…

Advertisement

Comments are closed.